With $1 billion assets under management, Israeli health-tech venture capital aMoon has raised $660 million in commitments to its second fund aMoon2, making it the largest single VC fund in Israel.
Launched in April 2018, aMoon 2 seeks to harness untapped Israeli HealthTech innovation and capitalize on mid-late stage funding gaps in Israel and around the world.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
aMoon2 has already invested in four Israeli companies and a fifth in Silicon Valley, founded by an Israeli entrepreneur in the field of cartilage treatment startup CartiHeal, Biolojic Design, a drug development company, Ayala Pharmaceutical, targeted therapy company and Zebra Medical Vision, a deep learning software startup.
“We plan to leverage Israel’s ecosystem of breakthrough science and disruptive tech innovation to accelerate cure and reshape global healthcare.” said Dr. Yair Schindel. “This raise is a vote of confidence for the Israeli HealthTech ecosystem that extends beyond Israel’s borders, to include the sizable community of Israeli entrepreneurs and researchers in global hubs, such as Silicon Valley and Boston.”
“The convergence of medicine and technology is generating a wave of innovation capable of redefining medical care – beyond our imagination. This presents a unique opportunity both for impacting human life and for the investor community.” said aMoon’s anchor investor, Marius Nacht.
In May 2018, aMoon and Credit Suisse announced a strategic partnership to provide investors with direct access to the fast-growing health tech sector. Michel Degen, CEO of Credit Suisse Asset Management Switzerland and EMEA, said: “We believe our partnership with aMoon represents an attractive platform for investors, while providing the funding needed for disruptive businesses to drive the advancement of healthcare.”
